IP Library Granted Patent US 9,974,744
Granted Patent B2
US 9,974,744 · App. 13/787,265 · Granted May 22, 2018

Sustained release formulation of a non-steroidal anti-inflammatory drug

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,744
App. No.
13/787,265
Granted
May 22, 2018
Kind
B2
Abstract

Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Claims (20)

1. A method of treating pain and inflammation, comprising administering a formulation comprising one or more non-steroidal anti-inflammatory drugs encapsulated in a first aqueous phase of multivesicular liposomes, to a subject in need thereof by injection, wherein the multivesicular liposomes comprise at least one anionic amphipathic phospholipid and at least one neutral lipid, wherein the one or more non-steroidal anti-inflammatory drugs are selected from the group consisting of meloxicam, piroxicam, and diclofenac, and wherein the total concentration of the non-steroidal anti-inflammatory drug in the multivesicular liposomes formulation is at least about 1.0 mg/mL.

2. The method of claim 1 , wherein the formulation further comprises a pharmaceutically acceptable carrier for injection.

3. The method of claim 1 , wherein the multivesicular liposomes comprise cholesterol, one or more phosphatidylglycerols, including salts of the phosphatidylglycerols, and one or more triglycerides.

4. The method of claim 1 , wherein the multivesicular liposomes comprise DPPG, DEPC, and tricaprylin.

5. The method of claim 1 , wherein the multivesicular liposomes comprise lysine.

6. The method of claim 1 , wherein the multivesicular liposomes comprise glutamic acid.

7. The method of claim 1 , wherein said administration is subcutaneous injection.

8. The method of claim 1 , wherein said administration is intramuscular injection.

9. The method of claim 1 , wherein said administration is intraarticular injection.

10. The method of claim 1 , wherein said administration comprises wound infiltration by local injection into a wound margin.

11. The method of claim 1 , wherein administration is every 1 to 7 days.

12. The method of claim 1 , wherein said non-steroidal anti-inflammatory drug is diclofenac.

13. The method of claim 1 , wherein said non-steroidal anti-inflammatory drug is meloxicam.

14. The method of claim 1 , wherein said multivesicular liposomes comprise a pH modifier selected from the group consisting of an inorganic acid, an inorganic base, an organic acid, an organic base, and a combination thereof.

15. The method of claim 1 , wherein said non-steroidal anti-inflammatory drug is piroxicam.

16. The method of claim 1 , wherein said multivesicular liposomes are characterized by an internal pH of about 8 to about 9.

17. The method of claim 1 , wherein said multivesicular liposomes comprise a pH modifier in the first aqueous phase selected from the group consisting of an organic acid, an organic base, and a combination thereof.

18. The method of claim 17 , wherein said multivesicular liposomes comprise an organic acid.

19. The method of claim 17 , wherein said multivesicular liposomes comprise an organic base.

20. The method of claim 1 , wherein said administration comprises instillation into a wound.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
SECURITY INTEREST Recorded Jul 4, 2025
From: PACIRA PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071814/0792 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 31, 2023
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 063213/0864 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Dec 14, 2021
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; FLEXION THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058516/0636 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2018
From: GARCIA, LOUIE DANIEL; ZHU, LIANGJIN; LAMBERT, WILLIAM JOSEPH; PATOU, GARY
To: PACIRA PHARMACEUTICALS, INC.
Reel/Frame 044575/0248 →